Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 17/20 | 1.00 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22000020 | 0.76 | ACLY (1.00) | ACLYALPL | |
| SCHEMBL4285713 | 0.75 | EGFR (0.70) | ACLYEGFRFGFR1KDR | |
| SCHEMBL22000019 | 0.73 | ACLY (0.74) | ACLYALPL | |
| SCHEMBL21999815 | 0.73 | ACLY (1.00) | ACLYALPL | |
| SCHEMBL14433781 | 0.72 | ACLY (0.75) | ACLYALPL | |
| SCHEMBL23389493 | 0.72 | ALDH1A1 (0.58) | ACLY | |
| SCHEMBL21931122 | 0.71 | ACLY (0.64) | ACLYALPL | |
| SCHEMBL21999615 | 0.71 | ACLY (1.00) | ACLYALPL | |
| SCHEMBL4294795 | 0.70 | ACLY (0.53) | ACLYEGFRFGFR1KDR | |
| SCHEMBL4294936 | 0.70 | ACLY (0.54) | ACLYEGFRFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885ALPL 603/4885EGFR 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.